Astrazeneca/Heptares to investigage GPCR targets

July 2011
Worldwide Biotech;Jul2011, Vol. 23 Issue 7, p4
Trade Publication
The article reports that AstraZeneca/Heptares has joined a 4-year cooperation on research and development of drugs that use G-protein coupled receptors. The cooperation adds various technologies used in the medicine development like StaR (r) technology and seeks to devise treatment and cures for central nervous pain, cardiovascular and inflammatory diseases. AstraZeneca will have the commercial rights to market products produced out of the cooperation while Heptares will be provided 6.25 million dollars in cash with committed research grant.


Related Articles

  • HEPTARES EXTENDS GLOBAL PATENT PROTECTION.  // Biotech Financial Reports;Jan2015, Vol. 22 Issue 1, p4 

    The article focuses on multiple key patents granted to Heptares Therapeutics Ltd. in the U.S. related to its G protein-coupled receptors-focused drug discovery platform. The patents granted by the U.S. Patent Office covers Heptares technology platform for development of thermostabilised G...

  • Heptares Raises $30M for Therapeutic Pipeline.  // Bioworld Week;3/2/2009, Vol. 17 Issue 9, p4 

    The article reports on the decision of Heptares Therapeutics Ltd. to raise £21 million in its first round of formal funding for therapeutic pipeline in London, England. The money will be used to fund Heptares for three years to develop its own pipeline of small-molecule drug candidates using...

  • Heptares and Takeda Initiate Drug Discovery Collaboration. Hobbs, Heather // International Labmate;2011, Vol. 36 Issue 4, p63 

    The article focuses on a two-year drug discovery collaboration formed by Heptares Therapeutics and Takeda Pharmaceutical Co. that is focused on a single G-protein coupled receptor (GPCR).

  • Heptares Raises $30M Series A to Boost Therapeutic Pipeline. Moran, Nuala // BioWorld International;2/25/2009, Vol. 14 Issue 8, p1 

    The article reports on the first round of formal funding held by Heptares Therapeutics Ltd. in Great Britain. The company has a platform technology StaR which makes it possible to discover and develop drugs against G-protein-coupled receptors that are acknowledged to be important targets but...

  • HEPTARES DEPLOYS STARS FOR SCREENING GPCR DRUG TARGETS.  // Worldwide Biotech;May2011, Vol. 23 Issue 5, p5 

    The article focuses on Heptares Therapeutics Ltd.'s use of Heptares StaR technology on G-protein-coupled receptors (GPCR) study. The StaR technology allowed the company to obtain GPCR resolutions with both Biophysical Mapping and X-ray crystallography methods, which was deemed impossible using...

  • HEPTARES & MEDIMMUNE COMPLETE ANTIBODY DISCOVERY.  // Worldwide Biotech;Mar2014, Vol. 26 Issue 3, p1 

    The article reports on Heptares Therapeutics' completion of the research phase of its antibody discovery collaboration with MedImmune. It explains that Heptares has delivered thermostabilized G protein-coupled receptors (GPCR) called StaR proteins for MedImmune's drug targets. The company has...

  • CLINIC ROUNDUP.  // BioWorld Today;12/10/2013, Vol. 24 Issue 236, p10 

    This section offers North American biopharmaceutical news briefs. Heptares Therapeutics Inc. began a Phase I study of HTL9936 to improve cognitive function in Alzheimer's disease to evaluate the pharmacokinetics of the drug. Intra-Cellular Therapies Inc. has reported positive top-line results...

  • HEPTARES AND ASTRAZENECA ENTER LICENSING AGREEMENT.  // Audiotex Update;Sep2015, Vol. 27 Issue 9, Special section p6 

    The article reports on a licensing agreement entered between Heptares Therapeutics and pharmaceutical company AstraZeneca. It states that the licensing agreement is designed to acquire exclusive global rights for the adenosine A2A receptor antagonist called HTL-1071. Comments from Susan...

  • HEPTARES AWARDED $5.5 MILLION GRANT FROM NIDA.  // Biotech Financial Reports;Nov2015, Vol. 22 Issue 11, p1 

    The article reports that Heptares Therapeutics ("Heptares"), subsidiary of biopharmaceutical company Sosei Group Corp. has received grants from the National Institute on Drug Abuse (NIDA). It mentions the grant will support Heptares' three-year research project to develop antagonist for the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics